摘要
目的:探讨索拉非尼联合肝动脉灌注化疗对晚期肝癌患者肝功能指标及生活质量改善状况的影响。方法:回顾性分析2019年1月-2020年1月本院60例肝癌患者的临床资料,依据治疗方法分为对照1组、对照2组与研究组,每组20例。对照1组采用单纯索拉非尼,对照2组采用肝动脉灌注化疗,研究组采用索拉非尼和肝动脉灌注治疗。比较三组肝功能指标、肝癌组织凋亡因子水平、生活质量改善情况及不良反应发生情况。结果:治疗前,三组ALT、TBIL、ALB比较,差异均无统计学意义(P>0.05);治疗6周,研究组ALT、TBIL和ALB均高于对照1组和对照2组,差异均有统计学意义(P<0.05)。治疗6周,对照1组与对照2组ALT、TBIL和ALB比较,差异均无统计学意义(P>0.05)。治疗6周,三组ALT、TBIL、ALB比较,差异均有统计学意义(P<0.05)。研究组端粒酶、c-Met及FasL指标均低于对照1组和对照2组,Fas指标高于对照1组和对照2组,差异均有统计学意义(P<0.05)。对照1组端粒酶、c-Met及FasL指标均高于对照2组,Fas指标低于对照2组,差异均有统计学意义(P<0.05)。研究组生活质量改善情况均优于对照1组和对照2组,恶化情况均低于对照1组与对照2组,差异均有统计学意义(P<0.05)。三组生活质量稳定情况比较,差异无统计学意义(P>0.05)。三组毒副反应发生率比较,差异无统计学意义(P>0.05)。结论:对晚期肝癌患者采用索拉非尼与肝动脉灌注化疗相结合,能降低肝癌组织凋亡因子水平,改善生活质量,且患者不良反应情况较少,具有较高的临床应用价值。
Objective:To investigate the effect of Sorafenib combined with hepatic artery infusion chemotherapy on the improvement of liver function indexes and quality of life in patients with advanced liver cancer.Method:The clinical data of 60 patients with liver cancer in our hospital from January 2019 to January 2020 were retrospectively analyzed and divided into control group 1,control group 2 and study group according to treatment methods,20 patients in each group.The control group 1 was treated with Sorafenib alone,the control group 2 was treated with hepatic artery infusion chemotherapy,and the study group was treated with Sorafenib combined with hepatic artery infusion.The indexes of liver function,the level of apoptotic factor of liver cancer tissue,the improvement of quality of life and the adverse of reaction were compared among three groups.Result:Before treatment,there were no significant differences in ALT,TBIL and ALB among three groups (P>0.05);after 6 weeks of treatment,ALT,TBIL and ALB of the study group were higher than those of the control group 1 and 2,the differences were statistically significant (P<0.05).After 6 weeks of treatment,there were no significant differences in ALT,TBIL and ALB between the control group 1 and 2 (P>0.05).After 6 weeks of treatment,there were statistically significant differences in ALT,TBIL and ALB among three groups (P<0.05).The indexes of telomerase,c-Met and FasL of the study group were lower than those of the control group 1 and 2,and the index of Fas of the study group was higher than those of the control group 1 and 2,the differences were statistically significant (P<0.05);the indexes of telomerase,c-Met and FasL of the control group 1 were higher than those of the control group 2,while the Fas of the control group 1 was lower than that of the control group 2,the differences were statistically significant (P<0.05).The improvement of quality of life of the study group was superior than those of the control group 1 and 2,and the deterioration was lower than those of the
作者
冯丽娟
谢建立
花雪娇
FENG Lijuan;XIE Jianli;HUA Xuejiao(The Third People’s Hospital of Shunde District in Foshan City,Foshan 528311,China;不详)
出处
《中国医学创新》
CAS
2021年第21期24-28,共5页
Medical Innovation of China
基金
2019年佛山市自筹经费类科技计划项目(医学类科技攻关项目)(1920001001140)。
关键词
索拉非尼
肝动脉灌注化疗
晚期肝癌
Sorafenib
Hepatic arterial infusion chemotherapy
Advanced liver cancer
